All News

Dr. Joshua K. Sabari sat down with Dr. Daniel V. Araujo to discuss topline takeaways from the 2025 ASCO Meeting across the realm of genitourinary oncology

The U.S. FDA has approved treatment with Ibtrozi for patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer.

Two people connect by sharing their experiences about taking care of their spouses who died from cancer, and the realization that sparked something more.

Treatment with the investigational therapeutic rusfertide has proven to be a potential treatment option for patients with polycythemia vera.

FDA granted priority review to Zepzelca plus Tecentriq for first-line maintenance in extensive-stage small cell lung cancer.

Amanda Snyder, a cancer survivor, became an oncology nurse to provide support she once lacked, now leading innovative therapies for patients.

Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.

Dr. Suresh Ramalingam discusses how Tagrisso has ushered in a new era of care for patients with advanced EGFR+ non-small cell lung cancer.

I survived breast cancer and medical trauma, but the road was brutal. Fifteen years later, I’m alive, scarred and still searching for peace.

The FDA grants fast track designation to PHST001, an antibody targeting CD24, for advanced platinum-resistant and platinum-sensitive ovarian cancer.

The VERIFY trial explores rusfertide to manage polycythemia vera without causing iron deficiency symptoms, Dr. Aaron Gerds explained.

Five years after my transplant for leukemia, I’m learning to focus on gratitude despite daily struggles, remembering that being alive is the greatest gift.

Michelle Kirschner discusses the how patients can foster a strong network of supporters from diagnosis through survivorship.

Natalie Schnaitmann discusses the importance of self-advocacy and access to second opinions when symptoms are dismissed among young women with cancer.

When it comes to living with cancer, your nurses make a difference.

The antibody-drug conjugate zilovertamab vedotin plus Rituxan and chemotherapy showed an objective response rate of 56.3% in relapsed/refractory DLBCL.

The first patient has been dosed in the phase 3 TERZO trial of Copiktra for relapsed or refractory nodal T-follicular helper cell lymphoma.

It is important to understand why it is vital that patients and survivors of cancer take steps to reduce the body’s burden both before and after treatment.

Dr. Jared Weiss walks patients through the therapeutic potential viability of intratumoral therapies among those with lung cancer.

Using a 14-gene test to guide chemotherapy significantly improved disease-free survival in patients with early nonsquamous lung cancer.

How artificial intelligence is being used to augment the work of experts treating patients with prostate cancer.

The dual-targeting CAR T-cell therapy KITE-363 showed positive response rates and manageable side effects in relapsed or refractory B-cell lymphoma.

Adding Zyprexa to ondansetron cut nausea and vomiting safely in abdominal/pelvic radiation with low-emetogenic capecitabine.

Adding subcutaneous sasanlimab to BCG improved recurrence-free survival in non–muscle-invasive bladder cancer, according to Dr. Petros Grivas.

CURE spoke with the principal investigator of a clinical trial evaluating a therapeutic vaccine for patients with advanced kidney cancer.

I describe what it is like to have an “invisible” cancer.

The FDA granted orphan drug designation to MVdeltaC, a measles virus-based immunotherapy, for pleural mesothelioma, supporting its future development.

Patients with oligometastatic lung cancer may live longer with surgery, but experts stress the need for multidisciplinary evaluation to guide treatment choices.